To refine the therapeutic efficacy of Doxil® in hepatocellular carcinoma (HCC), Wang et al. [87] chose a post-insertion strategy to modify PEGylated liposomal DOX with the bivalent fragment HAb18 F(ab’)2 named Metuximab, which resulted in increased antitumor efficacy in CD147-overexpressing liver cancer cells and Huh-7 tumor xenografts. This evidence concerns the gene BSG and hepatocellular carcinoma.